76.22
price up icon1.64%   1.23
after-market After Hours: 77.37 1.15 +1.51%
loading
Edwards Lifesciences Corp stock is traded at $76.22, with a volume of 3.59M. It is up +1.64% in the last 24 hours and up +0.24% over the past month. Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
See More
Previous Close:
$74.99
Open:
$75.46
24h Volume:
3.59M
Relative Volume:
0.80
Market Cap:
$44.71B
Revenue:
$5.54B
Net Income/Loss:
$4.18B
P/E Ratio:
10.89
EPS:
7
Net Cash Flow:
$623.10M
1W Performance:
-2.07%
1M Performance:
+0.24%
6M Performance:
+5.76%
1Y Performance:
-13.37%
1-Day Range:
Value
$75.28
$76.47
1-Week Range:
Value
$74.20
$77.77
52-Week Range:
Value
$58.93
$95.25

Edwards Lifesciences Corp Stock (EW) Company Profile

Name
Name
Edwards Lifesciences Corp
Name
Phone
(949) 250-2500
Name
Address
ONE EDWARDS WAY, IRVINE, CA
Name
Employee
15,800
Name
Twitter
@edwardslifesci
Name
Next Earnings Date
2025-02-11
Name
Latest SEC Filings
Name
EW's Discussions on Twitter

Compare EW with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Medical Devices icon
EW
Edwards Lifesciences Corp
76.22 45.66B 5.54B 4.18B 623.10M 7.00
Medical Devices icon
ABT
Abbott Laboratories
132.94 235.23B 42.34B 13.50B 6.66B 7.71
Medical Devices icon
BSX
Boston Scientific Corp
106.17 157.62B 17.55B 2.03B 2.72B 1.37
Medical Devices icon
SYK
Stryker Corp
383.78 148.87B 23.22B 2.86B 3.58B 7.40
Medical Devices icon
MDT
Medtronic Plc
81.18 110.72B 33.54B 4.66B 5.19B 3.62

Edwards Lifesciences Corp Stock (EW) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-24-25 Upgrade Piper Sandler Neutral → Overweight
Jan-30-25 Upgrade Stifel Hold → Buy
Jan-16-25 Downgrade Wolfe Research Peer Perform → Underperform
Dec-16-24 Upgrade BofA Securities Neutral → Buy
Oct-11-24 Resumed Morgan Stanley Equal-Weight
Sep-18-24 Downgrade Jefferies Buy → Hold
Jul-31-24 Upgrade Daiwa Securities Neutral → Outperform
Jul-29-24 Upgrade Wolfe Research Underperform → Peer Perform
Jul-25-24 Downgrade BofA Securities Buy → Neutral
Jul-25-24 Downgrade JP Morgan Overweight → Neutral
Jul-25-24 Downgrade Robert W. Baird Outperform → Neutral
Jul-25-24 Downgrade TD Cowen Buy → Hold
Jul-25-24 Downgrade Truist Buy → Hold
May-30-24 Initiated Goldman Buy
May-22-24 Upgrade Citigroup Neutral → Buy
May-14-24 Upgrade Deutsche Bank Hold → Buy
Mar-07-24 Upgrade BofA Securities Neutral → Buy
Feb-02-24 Upgrade Wells Fargo Equal Weight → Overweight
Jan-04-24 Downgrade Evercore ISI Outperform → In-line
Dec-11-23 Downgrade Citigroup Buy → Neutral
Nov-28-23 Downgrade Wolfe Research Peer Perform → Underperform
Sep-26-23 Upgrade Oppenheimer Perform → Outperform
Jul-19-23 Initiated Robert W. Baird Outperform
May-30-23 Resumed Morgan Stanley Overweight
Mar-29-23 Initiated UBS Neutral
Mar-08-23 Downgrade Wells Fargo Overweight → Equal Weight
Feb-06-23 Downgrade Raymond James Outperform → Mkt Perform
Jan-31-23 Downgrade Bernstein Outperform → Underperform
Jan-30-23 Downgrade Piper Sandler Overweight → Neutral
Dec-06-22 Downgrade Stifel Buy → Hold
Oct-28-22 Downgrade Oppenheimer Outperform → Perform
Oct-26-22 Initiated Mizuho Buy
Oct-18-22 Initiated Barclays Overweight
Oct-12-22 Initiated Jefferies Buy
Jul-29-22 Downgrade Canaccord Genuity Buy → Hold
Apr-13-22 Initiated Truist Buy
Apr-06-22 Initiated Wolfe Research Outperform
Mar-16-22 Upgrade Bernstein Mkt Perform → Outperform
Mar-02-22 Resumed BofA Securities Neutral
Feb-02-22 Upgrade UBS Neutral → Buy
Jan-27-22 Reiterated Citigroup Buy
Jan-27-22 Reiterated Evercore ISI Outperform
Jan-27-22 Reiterated Raymond James Outperform
Jan-27-22 Reiterated Stifel Buy
Jan-27-22 Reiterated UBS Neutral
Dec-17-21 Upgrade JP Morgan Neutral → Overweight
Dec-15-21 Upgrade Citigroup Neutral → Buy
Dec-10-21 Initiated RBC Capital Mkts Outperform
Dec-06-21 Upgrade Wells Fargo Equal Weight → Overweight
Jul-30-21 Reiterated Canaccord Genuity Buy
Jul-30-21 Reiterated Deutsche Bank Hold
Jul-30-21 Reiterated Jefferies Buy
Jul-30-21 Reiterated Morgan Stanley Overweight
Jul-30-21 Reiterated Oppenheimer Outperform
Jul-30-21 Reiterated Stifel Buy
Jul-30-21 Reiterated UBS Neutral
Jul-30-21 Reiterated Wells Fargo Equal Weight
May-25-21 Initiated Barclays Overweight
Apr-15-21 Initiated Atlantic Equities Neutral
Apr-05-21 Upgrade Evercore ISI In-line → Outperform
Dec-16-20 Downgrade Citigroup Buy → Neutral
Dec-11-20 Reiterated Canaccord Genuity Buy
Sep-11-20 Initiated Wolfe Research Underperform
Apr-28-20 Downgrade Wells Fargo Overweight → Equal Weight
Apr-17-20 Upgrade SVB Leerink Mkt Perform → Outperform
Mar-05-20 Initiated Citigroup Buy
Feb-13-20 Initiated Goldman Neutral
Feb-06-20 Resumed BTIG Research Neutral
Jan-10-20 Initiated Oppenheimer Outperform
Jan-02-20 Downgrade Evercore ISI Outperform → In-line
Oct-24-19 Reiterated Canaccord Genuity Buy
Sep-23-19 Initiated Piper Jaffray Overweight
Jul-24-19 Reiterated BofA/Merrill Buy
Mar-18-19 Reiterated Canaccord Genuity Buy
Jan-18-19 Upgrade BofA/Merrill Neutral → Buy
Jan-03-19 Initiated Deutsche Bank Hold
Nov-28-18 Initiated UBS Neutral
Oct-16-18 Initiated Barclays Underweight
Oct-02-18 Downgrade BofA/Merrill Buy → Neutral
Oct-02-18 Downgrade Guggenheim Buy → Neutral
View All

Edwards Lifesciences Corp Stock (EW) Latest News

pulisher
May 24, 2025

Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com

May 24, 2025
pulisher
May 23, 2025

Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech

May 23, 2025
pulisher
May 23, 2025

Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance

May 23, 2025
pulisher
May 23, 2025

Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance

May 23, 2025
pulisher
May 22, 2025

Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga

May 22, 2025
pulisher
May 22, 2025

Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice

May 22, 2025
pulisher
May 22, 2025

Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com

May 22, 2025
pulisher
May 22, 2025

Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com

May 22, 2025
pulisher
May 21, 2025

Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com

May 21, 2025
pulisher
May 20, 2025

Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing

May 18, 2025
pulisher
May 16, 2025

Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance

May 16, 2025
pulisher
May 15, 2025

Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post

May 15, 2025
pulisher
May 14, 2025

Edwards Lifesciences Completes Sale of Critical Care - Quantisnow

May 14, 2025
pulisher
May 14, 2025

Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq

May 14, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com

May 13, 2025
pulisher
May 12, 2025

FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal

May 12, 2025
pulisher
May 09, 2025

Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey

May 09, 2025
pulisher
May 08, 2025

Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus

May 08, 2025
pulisher
May 08, 2025

Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance

May 08, 2025
pulisher
May 06, 2025

Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan

May 06, 2025
pulisher
May 02, 2025

Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance

May 02, 2025
pulisher
May 01, 2025

Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com

May 01, 2025
pulisher
May 01, 2025

Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice

May 01, 2025
pulisher
May 01, 2025

Edwards TAVR Receives FDA Approval for Patients With Asymptomatic Severe Aortic Stenosis - BioSpace

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy By Investing.com - Investing.com India

May 01, 2025
pulisher
May 01, 2025

FDA approves Edwards Lifesciences’ TAVR therapy - Investing.com

May 01, 2025
pulisher
Apr 30, 2025

Edwards Lifesciences Corporation (EW): Jim Cramer Says It’s a Hold — But Is Boston Scientific Now His Favorite? - Insider Monkey

Apr 30, 2025
pulisher
Apr 28, 2025

Commit To Purchase Edwards Lifesciences At $60, Earn 6.8% Using Options - Nasdaq

Apr 28, 2025
pulisher
Apr 26, 2025

Edwards Lifesciences Corporation (NYSE:EW) Q1 2025 Earnings Call Transcript - Insider Monkey

Apr 26, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences Reports Robust Q1 2025 Growth - TipRanks

Apr 25, 2025
pulisher
Apr 25, 2025

Edwards Lifesciences (EW) Price Target Raised by Canaccord Analy - GuruFocus

Apr 25, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Raises 2025 Sales Forecast Amid Currency Boost - Finimize

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Stock Earns Analyst Upgrade As Growth Outlook BrightensEdwards Lifesciences (NYSE:EW) - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (NYSE:EW) Projects 2025 Sales Over US$5.7 Billion With Strong Earnings - Yahoo Finance

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences Corp (EW) Shares Up 7.25% on Apr 24 - GuruFocus

Apr 24, 2025
pulisher
Apr 24, 2025

This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga

Apr 24, 2025
pulisher
Apr 24, 2025

Stifel maintains Edwards Lifesciences stock with $90 target - Investing.com

Apr 24, 2025
pulisher
Apr 24, 2025

Bernstein Adjusts Price Target on Edwards Lifesciences to $80 From $78 - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Edwards Lifesciences (EW) Price Target Raised by Baird Amid Mixed Q1 Results | EW Stock News - GuruFocus

Apr 24, 2025

Edwards Lifesciences Corp Stock (EW) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$85.33
price up icon 0.97%
$71.01
price up icon 2.67%
medical_devices SNN
$28.92
price up icon 1.01%
medical_devices STE
$246.20
price up icon 1.32%
$326.64
price up icon 1.64%
Cap:     |  Volume (24h):